Neil Josephson, a University of Washington professor and former executive at Seagen Inc., has joined San Diego-area Iambic Therapeutics as chief medical officer.
Josephson, who is in the division of hematology, taught at UW for about 10 years as an assistant and associate professor, according to his LinkedIn page. Iambic said in a news release he is still on the faculty as a clinical associate professor.
“I am thrilled to join this leadership team and to help build an organization that can maximize the opportunity to rapidly advance and execute on a new generation of oncology drug candidates," Josephson said in the release.
An Iambic spokesperson said Josephson will remain in Seattle but will regularly travel to San Diego. He is replacing Jackie Walling, who had been Iambic's interim CMO.
Josephson started working at biotechnology companies in 2013, according to his LinkedIn page, when he began at Bothell-based cancer biotech Seagen. He spent more than five years at Seagen, which was acquired by Pfizer in December for $43 billion. His LinkedIn page notes his most recent role with Seagen was vice president of clinical development.
After leaving Seagen in 2019, Josephson spent close to four years at Vancouver, British Columbia-based Zymeworks. He eventually took the role of CMO there. In addition to its Vancouver headquarters, Zymeworks has offices in Bellevue, Singapore, Dublin and Redwood City, California.
Iambic, founded in 2019, has a variety of pre-clinical candidates aimed at cancer. Tom Miller, the company's co-founder and CEO, became a full professor at the California Institute of Technology in 2013. Iambic, formerly called Entos, raised a $100 million Series B round in October and a $53 million Series A round in 2021.
"Neil’s experience in successfully designing and leading oncology clinical studies, and his expertise in clinical research, operations, regulatory and medical affairs, will all be essential," Miller said in the release.
